D.E. Shaw & Co
RDHL

D.E. Shaw & Co’s Redhill Biopharma RDHL Stock Holding History

D.E. Shaw & Co’s Portfolio RDHL Stock Details RDHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-14
Closed -$113K – 3824
2019
Q1 		$113K Sell
14
-19
-58% -$150K ﹤0.01% 3474
2018
Q4 		$186K Buy
+33
New +$253K ﹤0.01% 3560

Other funds holding RDHL

6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $837M AUM 25.51% 1-Year Est. Return

D.E. Shaw & Co's RDHL Position: Q2 2019 in Review

D.E. Shaw & Co sold out of Redhill Biopharma (RDHL) in Q2 2019, closing a stake of 14 shares — an estimated $113K sold.

D.E. Shaw & Co first reported a position in RDHL in Q4 2018 and held it in 2 quarters. The position peaked at $186K in Q4 2018. 34 funds tracked by Wall St. Rank hold RDHL as of Q2 2019.

  • D.E. Shaw & Co reported no remaining Redhill Biopharma position as of Q2 2019 after selling out during the quarter.
  • D.E. Shaw & Co sold 14 Redhill Biopharma shares in Q2 2019, an estimated $113K.
  • D.E. Shaw & Co first reported a position in Redhill Biopharma in Q4 2018 and held it in 2 quarters.
  • D.E. Shaw & Co's Redhill Biopharma position peaked at $186K in Q4 2018.
  • 34 funds tracked by Wall St. Rank held Redhill Biopharma as of Q2 2019.

Based on D.E. Shaw & Co's 13F filing for Q2 2019, filed 14 Aug 2019.